Neuro-ophthalmology and paraneoplastic syndromes

Current Opinion in Neurology

Volumn 17, Issue 1, 2004, Pages 3-8

  Bataller, Luis ^a   Dalmau, Josep ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antineuronal antibodies; Opsoclonus; Paraneoplastic neuro ophthalmological syndromes

Indexed keywords

AUTOANTIGEN; CELL ANTIBODY; CRMP 5 ANTIBODY; HU PROTEIN; IMMUNOGLOBULIN G; M PROTEIN; MA 2 PROTEIN; PROTEIN ANTIBODY; RECOVERIN; RI ANTIBODY; TR ANTIBODY; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

BRAIN STEM INJURY; CENTRAL NERVOUS SYSTEM; CEREBELLAR ATAXIA; CEREBELLUM DEGENERATION; CRANIAL NEUROPATHY; DIPLOPIA; EATON LAMBERT SYNDROME; ENCEPHALITIS; EYE DISEASE; GAZE PARALYSIS; HUMAN; IMMUNITY; MELANOMA; MYOCLONUS; NEUROOPHTHALMOLOGY; OPSOCLONUS; OPTIC NERVE DISEASE; PARANEOPLASTIC SYNDROME; PTOSIS; RADICULOPATHY; RETINOPATHY; REVIEW; SYMPTOMATOLOGY; SYNAPSE; THYMOMA; UVEITIS;

AUTOANTIBODIES; AUTOANTIGENS; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEURONS; OCULAR MOTILITY DISORDERS; OCULOMOTOR NERVE DISEASES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; RETINAL DISEASES;

EID: 1542269077     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200402000-00003     Document Type: Review

References (56)

1. Posner JB. Neurologic complications of cancer. Philadelphia: F.A. Davis Company; 1995.
2. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997; 24:318-328.
3. Henson RA, Urich HE. Cancer and the nervous system: the neurological manifestations of systemic malignant disease. London: Blackwell Scientific; 1982.
4. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120:1279-1300.
5. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931-1937.
6. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230-234. This multicenter study broadens the clinical and immunological associations of patients with anti-Tr antibodies.
7. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241-251.
8. Dalmau J, Gultekin SH, Voltz R, et al. Ma 1, a novel neuron-and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122:27-39.
9. Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61:270-278.
10. Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42:1938-1943.
11. Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764-766. This paper provides proof of the intrathecal synthesis of anti-VGCC antibodies in patients with paraneoplastic CNS dysfunction.
12. Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:21-28. This study suggests a role for antibodies against P/Q-type VGCCs of the cerebellum in the pathophysiology of paraneoplastic cerebellar ataxia in some patients with SCLC.
13. Sillevis SP, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342:21-27.
14. Coesmans M, Sillevis-Smitt P, Linden DJ, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53:325-336. The authors report experimental data supporting the hypothesis that anti-mGluR1 antibodies may cause cerebellar dysfunction.
15. Baloh RW, DeRossett SE, Cloughesy TF, et al. Novel brainstem syndrome associated with prostate carcinoma. Neurology 1993; 43:2591-2596.
16. Dalmau J, Graus F, Rosenblum MK, et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59-72.
17. Saiz A, Dalmau J, Butler MH, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J. Neurol Neurosurg Psychiatry 1999; 66:214-217.
18. Bennett JL, Galetta SL, Frohman LP, et al. Neuro-ophthalmologic manifestations of a novel paraneoplastic syndrome associated with testicular carcinoma. Neurology 1999; 52:864-867.
19. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340:1788-1795.
20. Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339-348.
21. Bataller L, Wade D, Fuller G, et al. Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum. Neurology 2002; 59:1985-1987. The authors report the cloning of Zic proteins as molecular targets of granule cell antibodies present in the serum and CSF of a patient with subacute cerebellar degeneration.
22. Bataller L, Wade DF, Rosenfeld MR, Dalmau J. Immunity to Zic proteins frequently associates with paraneoplastic neurologic disorders (PND) and predicts small-cell lung cancer (SCLC). Ann Neurol 2002; 52 (Suppl):S80. This study presents preliminary data showing the association between anti-Zic immunity, paraneoplastic cerebellar degeneration and SCLC.
23. Leigh RJ, Zee DSE. The neurology of eye movements. New York: Oxford University Press; 1999.
24. Pranzatelli MR, Tate ED, Kinsbourne M, et al. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord 2002; 17:1387-1390. An interesting clinical observation describing the long-term outcome of a patient with idiopathic early-onset opsoclonus-myoclonus.
25. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437-443.
26. Hersh B, Dalmau J, Dangond F, et al. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology 1994; 44:1754-1755.
27. Rojas-Marcos I, Rousseau A, Keime-Guibert F, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82:216-223. An extensive review of the clinical and immunological associations of a large series of patients with breast or gynecological cancers and paraneoplastic neurological dysfunction.
28. Sutton I, Barnett M, Watson J, et al. Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol 2002; 249:1597-1598. The authors report a patient with renal cancer, anti-Ri antibodies, and multiple paraneoplastic neuro-ophthalmological findings. A review of 22 patients with anti-Ri immunity showed that although 21 had neuro-ophthalmological findings, only 11 developed opsoclonus. The tumor most frequently involved was breast cancer.
29. Pittock S, Lucchinetti C, Lennon V. Anti-neuronal nuclear autoantibody type-2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580-587. The clinical description of a series of 34 patients with anti-Ri antibodies (ANNA-2). Lung cancer was the tumor most frequently found.
30. Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22:315-320.
31. Pranzatelli M, Tate E, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus ataxia. Pediatr Neurol 2003; 27:384-387. In this study, all 59 children with opsoclonus-myoclonus syndrome studied were seronegative for anti-Hu, anti-Ri, and anti-Yo antibodies.
32. Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53:347-353. The authors report the serological screening of a cDNA brainstem library with the sera of 21 patients with the opsoclonus-myoclonus syndrome. A variety of neuronal antigens were cloned, suggesting heterogeneous immune mechanisms in the pathophysiology of this syndrome.
33. Kloos L, Sillevis-Smitt P, Ang C, et al. Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J. Neurol Neurosurg Psychiatry 2003; 74:507-509. The first report of a patient with melanoma and paraneoplastic neuropathy with ophthalmoplegia. Anti-GQ1b antibodies that cross-reacted with the tumor were found.
34. Odaka M, Yuki N, Hirata K. Anti-GQ1b antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50-55.
35. Vincent A. Antibodies to ion channels in paraneoplastic disorders. Brain Pathol 1999; 9:285-291.
36. Wirtz P, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002; 73:766-768. The authors describe interesting differences between the distribution of motor weakness in patients with MG and LEMS.
37. Burns T, Russell J, LaChance D, Jones H. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:270-273. Oculobulbar symptoms are more frequent than previously thought in patients with LEMS; their presence should not dissuade clinicians from the diagnosis of this disorder.
38. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48:1246-1252.
39. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7:365-368.
40. Sanders D, El-Salem K, Massey J, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003; 60:1978-1980. This study highlights the importance of determining MuSK antibodies in the clinical management of patients with seronegative MG. The findings indicate that treatment with plasmapheresis should be especially considered in this subset of patients.
41. Evoli A, Tonali P, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126:2304-2311. The authors report their clinical experience with 37 patients with MG and MuSK antibodies. Interesting observations about diagnosis and treatment of atypical seronegative MG patients are made.
42. Voltz RD, Albrich WC, Nagele A, et al. Paraneoplastic myasthenia gravis: detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor. Neurology 1997; 49:1454-1457.
43. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001; 57:1579-1582.
44. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111:577-596.
45. Nakao Y, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome. Study of 110 Japanese patients. Neurology 2002; 59:1773-1775. This study reports the clinical features of patients with seronegative LEMS. The results of passive transfer experiments suggest that seronegative LEMS is also mediated by antibodies.
46. Keltner JL, Thirkill CE. Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 1998; 126:296-302.
47. Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9-and caspase 3-dependent pathway. J Neuroimmunol 2002; 132:72-82. This article provides experimental data suggesting that recoverin antibodies play a pathogenic role in paraneoplastic retinal degeneration.
48. Ohguro H, Marayuma I, Nakzawa M, Oohira A. Antirecoverin antibody in the aqueous humor of a patient with cancer-associated retinopathy. Am J Ophthalmol. 2002; 134:605-607. The authors provide evidence that recoverin antibodies can gain access to the aqueous humor of the eye.
49. Kikuchi T, Arai J, Shibuki H, et al. Tubby-like protein 1 as an autoantigen in cancer-associated retinopathy. J Neuroimmunol 2000; 103:26-33.
50. Eichen J, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol 2001; 21:168-172.
51. Tateiwa H, Gotoh N, Ichikawa M, et al. Molecular cloning and characterization of human PTB-like protein: a possible retinal autoantigen of cancer-associated retinopathy. J Neuroimmunol 2001; 161-169.
52. Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:91-100.
53. Potter M, Adamus G, Szabo S, et al. Autoantibodies to transducin in a patent with melanoma-associated retinopathy. Am J Ophthalmol 2003; 134:128-130. The report of a novel reactivity in a patient with melanoma-associated retinopathy.
54. Keltner J, Thirkill C, Yip P. Clinical and immunological characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J. Neuroophthalmol 2003; 21:173-187. A review of the clinical and immunological findings in 62 patients with melanoma-associated retinopathy. Several patterns of reactivity were found by immunohistochemistry.
55. de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405-408.
56. Cross S, Salomao D, Parisi J, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38-50. The authors report 16 patients with optic neuritis, retinitis or both, selected from a large series of patients with anti-CV2/CRMP5 antibodies and paraneoplastic encephalomyelitis. Most patients had SCLC and 62.5% of patients with visual disorders also had other antibodies.